Jack L. LEONARD;University Of Massachusetts;Deborah M. LEONARD;Karl J. SIMIN
发明人:
Jack L. LEONARD,Karl J. SIMIN,Deborah M. LEONARD
申请号：
IL25877118
公开号：
IL258771D0
申请日:
2018.04.17
申请国别(地区):
IL
年份:
2018
代理人:
摘要：
The invention relates to the discovery of a vital new component of the Wnt pathway that regulates trafficking of β-catenin to the cell nucleus and novel therapeutic approaches to cancer treatment. Disclosed herein is a previously unknown, essential component of the Wnt/β-catenin signaling pathway that governs the quantity of β-catenin delivered to the cell nucleus. This intracellular inhibitor of β-catenin signaling (IBS) is transcribed from a second transcriptional start site adjacent to exon 3 of the Dkk3 gene and is required for early mouse development. IBS captures β-catenin destined for the nucleus in a complex with β-TrCP that is bound to the actin cytoskeleton and unavailable for nuclear translocation.
